Cognitive function and quality of life in ovarian cancer

Gynecologic Oncology

Volumn 124, Issue 3, 2012, Pages 404-409

  Correa, Denise D ^a   Hess, Lisa M ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Cognitive function; Ovarian cancer; Quality of life

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; PACLITAXEL; PLACEBO; PLATINUM; TANOMASTAT; TOPOTECAN;

ADVANCED CANCER; ARTICLE; ATTENTION; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER SURVIVAL; COGNITION; COGNITIVE DEFECT; HUMAN; MOTOR PERFORMANCE; MULTIPLE CYCLE TREATMENT; NEUROPSYCHOLOGY; OUTCOME ASSESSMENT; OVARY CANCER; PERCEPTION; PERITONEUM CANCER; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; RECURRENT CANCER; UTERINE TUBE CARCINOMA;

ADULT; AGED; COGNITION; COGNITION DISORDERS; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; QUALITY OF LIFE; SELF REPORT;

EID: 84856747953     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.11.005     Document Type: Article

References (68)

1. I.F. Tannock, T.A. Ahles, and P.A. Ganz Cognitive impairment associated with chemotherapy for cancer: report of a workshop J Clin Oncol 22 11 2004 2233 2239
2. D.D. Correa, and T.A. Ahles Neurocognitive changes in cancer survivors Cancer J 14 6 2008 396 400
3. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer Statistics, 2010 CA Cancer J Clin 60 2010 277 300
4. W.P. McGuire III, and M. Markman Primary ovarian cancer chemotherapy: current standards of care Br J Cancer 89 Suppl. 3 2003 S3 S8
5. J. Morrison, A. Swanton, S. Collins, and S. Kehoe Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer Cochrane Database Syst Rev 4 17 2007 CD005343
6. L.M. Hess, and K.C. Insel Chemotherapy-related change in cognitive function: a conceptual model Oncol Nurs Forum 34 5 2007 981 994
7. T.A. Ahles, A.J. Saykin, and C.T. Furstenberg Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma J Clin Oncol 20 2 2002 485 493
8. C.B. Brezden, K.A. Phillips, and M. Abdolell Cognitive function in breast cancer patients receiving adjuvant chemotherapy J Clin Oncol 18 14 2000 2695 2701
9. S.B. Schagen, F.S. van Dam, and M.J. Muller Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma Cancer 85 3 1999 640 650
10. K.A. Donovan, B.J. Small, and M.A. Andrykowski Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma Cancer 104 2005 2499 2507
11. A. Scherwath, A. Mehnert, and B. Schleimer Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects Ann Oncol 17 3 2006 415 423
12. J.S. Wefel, R. Lenzi, and R.L. Theriault The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial Cancer 100 11 2004 2292 2299
13. T.A. Ahles, A.J. Saykin, and B.C. McDonald Cognitive function in breast cancer patients prior to adjuvant treatment Breast Cancer Res Treat 110 1 2008 143 152
14. V. Jenkins, V. Shilling, and G. Deutsch A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer Br J Cancer 94 6 2006 828 834
15. A. Paganini-Hill, and L.J. Clark Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen Breast Cancer Res Treat 64 2 2000 165 176
16. V. Jenkins, V. Shilling, and L. Fallowfield Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study Psychooncology 13 1 2004 61 66
17. C.M. Bender, S.M. Sereika, and A.M. Brufsky Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer Menopause 14 6 2007 995 998
18. C.M. Schilder, C. Seynaeve, and L.V. Beex Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial J Clin Oncol 28 2010 1294 1300
19. W.A. Rocca, J.H. Bower, and D.M. Maragonore Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause Neurology 68 2007 1074 1083
20. M.C. Craig, P.C. Fletcher, and E.M. Daly The interactive effect of the cholinergic system and acute ovarian suppression in the brain: an fMRI study Horm Behav 55 2009 41 49
21. K.J. Vearncombe, and N.A. Pachana Is cognitive functioning detrimentally affected after early, induced menopause? Menopause 16 2009 188 198
22. M.K. Tuxen, and H.S. Werner Neurotoxicity secondary to antineoplastic drugs Cancer Treat Rev 20 1994 191 214
23. J. Dietrich, R. Han, and Y. Yang CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and vivo J Biol 5 2006 1 23
24. M. Inagaki, E. Yoshikawa, and Y. Matsuoka Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy Cancer 109 2007 146 156
25. B.C. McDonald, S.K. Conroy, and T.A. Ahles Gray matter reduction associated with systemic chemotherapy for breast cancer: prospective MRI study Breast Cancer Res Treat 123 2010 819 828
26. T.A. Ahles, A.J. Saykin, and W.W. Noll The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy Psychooncology 12 2003 612 619
27. T.A. Ahles, and A.J. Saykin Candidate mechanisms for chmeotherapy-induced cognitive changes Nat Rev Cancer 7 2007 192 201
28. A.E. Kayl, and C.A. Meyers Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients Curr Opin Obstet Gynecol 18 2006 24 28
29. J.S. Wefel, M.E. Witgert, and C.A. Meyers Neuropsychological sequelae of non-central nervous system cancer and cancer therapy Neuropsychol Rev 18 2008 121 131
30. K. Mayerhofer, B. Bodner-Adler, and K. Bodner A paclitaxel-containing chemotherapy does not cause central nervous adverse effects: a prospective study in patients with ovarian cancer Anticancer Res 20 2000 4051 4055
31. A.P. Kudelka, A. Hasenburg, and C.F. Verschraegen Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma Anti-Cancer Drugs 9 1998 405 409
32. M.L. Hensley, D.D. Correa, and H. Thaler Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning Gynecol Oncol 102 2006 270 277
33. L.M. Hess, S.K. Chambers, and K. Hatch Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer J Surg Oncol 8 2010 252 258
34. D.D. Correa, Q. Zhou, and H.T. Thaler Cognitive functions in long-term survivors of ovarian cancer Gynecol Oncol 119 2010 366 369
35. L.N. Arriba, A.N. Fader, and H.E. Frasure A review of issues surrounding quality of life among women with ovarian cancer Gynecologic Oncol 119 2010 390 396
36. B. Kirshner, and G.H. Guyatt A methodological framework for assessing health indices J Chron Dis 38 1988 27 36
37. D.F. Cella, D.S. Tuslky, and G. Gray The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure J Clin Oncol 11 1993 570 579
38. A. Coates, F. Dillenbeck, and D.R. McNeil On the receiving end-II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy Eur J Cancer Clin Oncol 19 11 1984 1633 1637
39. A.B. Kornblith, H.T. Thaler, and G. Wong Quality of life in women with ovarian cancer Gyn Onc 59 1995 231 242
40. C.M. Lakusta, M.J. Atkinson, and J.W. Robinson Quality of life in ovarian cancer patients receiving chemotherapy Gyn Onc 81 2001 490 495
41. D.G. Mutch, M. Orlando, and T. Goss Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer J Clin Oncol 25 19 2007 2811 2818
42. A.H. Liavaag, A. Dørum, and S.D. Fosså Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones? J Clin Oncol 25 15 2007 2049 2056
43. K.M. Schmeler, S. Vadhan-Raj, and P.T. Ramirez A phase II study of GM-CSF and rIFN-γ1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer Gyn Onc 113 2009 210 213
44. T.A. Ahles, and D.D. Correa Neurocognitice changes in cancer survivors Cancer J 14 2008 396 400
45. S.A. Castellon, P.A. Ganz, and J.E. Bower Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen J Clin Exp Neuropsychol 26 2004 955 969
46. M.C. Dux, J.L. Woodard, and J.E. Calamari The moderating role of negative affect on objective verbal memory performance and subjective memory complaints in healthy older adults J Int Neuropsychol Society 14 2008 327 336
47. A.K. Troyer, and J.B. Rich Psychometric properties of a new metamemory questionnaire for older adults J Gerontol 57 2002 19 27
48. A.J. Saykin, H.A. Wishart, and L.A. Rabin Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI Neurology 67 2006 834 842
49. R.J. Ferguson, B.C. McDonald, and A.J. Saykin Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy J Clin Oncol 25 2007 3866 3870
50. B. Cimprich, H. So, and D.L. Ronis Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer Psychooncology 14 1 2005 70 78
51. M. Liik, L. Vahter, and K. Gross-Paju Subjective complaints compared to the results of neuropsychological assessment in patients with epilepsy; the influence of comorbid depression Epilepsy Res 84 2009 194 200
52. C. Fischer, T.A. Schweizer, and J.H. Atkins Neurocognitive profiles in older adults with an without major depression Int J Geriatr Psychiatry 23 2008 851 856
53. M.J. Slavin, H. Brodaty, and N.A. Kochan Prevalence and predictors of "subjective cognitive complaints" in the Sydney Memory and Ageing Study Am J Geriatr Psychiatry 18 2010 701 710
54. P. Fayers, and A. Bottomley EORTC Quality of Life Group and the Quality of Life Unit. Quality of life research within the EORTC-the EORTC QLQ-C30 Eur J Cancer 34 2002 125 133
55. D. Osoba, B. Zee, and J. Pater Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer Qual Life Res 3 1994 353 364
56. M.S. Carey, M. Bacon, and D. Tu The prognostic effects of performance status and quality of life scores on progression-free and overall survival in advanced ovarian cancer Gyn Onc 108 2008 100 105
57. H. Hirte, I.B. Vergote, and J.R. Jeffrey A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study Gyn Onc 102 2006 300 308
58. E.F. Greimel, V. Bjelic-Radisic, and J. Pfisterer Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel J Clin Oncol 24 4 2006 579 586
59. Y.M. Chan, T.Y. Ng, H.Y.S. Ngan, and L.C. Wong Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study Gyn Onc 88 2003 9 16
60. B. Holzner, G. Kemmler, and V. Meraner Fatigue in ovarian carcinoma patients: a neglected issue? Cancer 97 2003 1564 1572
61. V.E. Von Gruenigen, H.Q. Huang, and K.M. Gil Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials Cancer 115 2009 4857 4864
62. V.E. Von Gruenigen, H.Q. Huang, and K.M. Gil A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group Study J Pain Symptom Mgmt 39 5 2010 839 846
63. A.J. González-Martín, E. Calvo, and I. Bover Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) study Ann Oncol 16 2005 749 755
64. I. Steppan, D. Reimer, and U. Sevelda Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin: an evaluation of the therapeutic index with special emphasis on cardiac toxicity Chemotherapy 55 2009 391 398
65. J. Sehouli, D. Stengel, and G. Oskay-Oezcelik Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group J Clin Oncol 26 19 2008 3176 3182
66. A. Bezjak, D. Tu, M. Bacon, and D. Osoba Quality of life in ovarian cancer patients: comparison of paclitaxel plus cispatin, with cyclophosphamide plus cisplatin in a randomized study J Clin Oncol 22 2004 4595 4603
67. J. Vardy, J. Wong, and Q.L. Yi Assessing cognitive function in cancer patients Support Care Cancer 14 11 2006 1111 1118
68. L.I. Wagner, J.S. Lai, D. Cella, J. Sweet, and S. Forrestal Chemotherapy-related cognitive deficits: development of the Fact-Cog instrument Ann Behav Med 27 2004 S10